MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Parkinson’s"

  • 2023 International Congress

    Olfactory discrimination ability is associated with subjective lack of social support in female Parkinson’s patients

    T. Blum, L. Consortium, R. Dodel (Essen, Germany)

    Objective: We aimed to explore the relationship between olfactory discrimination ability and subjective social support in a sample of patients with Parkinson’s Disease. We hypothesized…
  • 2023 International Congress

    Drooling is associated with disease severity in Parkinson’s disease

    N. Nishikawa, E. Ikami, H. Takeshige, T. Ogawa, T. Hatano, N. Hattori (Tokyo, Japan)

    Objective: To investigate frequency of PD patients with symptoms of drooling and their clinical characteristics in our Japanese Parkinson's disease (PD) registry data. Background: Drooling…
  • 2023 International Congress

    Healthcare experiences of People with Parkinson’s Disease (PwP) during COVID-19 pandemic

    V. Tomantschger, A. Tautscher-Basnett, C. Hohenwarter (Hermagor, Austria)

    Objective: To investigate how our group of PwP coped with healthcare issues during the pandemic. Background: COVID-19 pandemic led to changes in how healthcare services…
  • 2023 International Congress

    Local field potentials can guide programming of Deep Brain Stimulation in Parkinson’s Disease

    B. Seegmiller, P. Coss (San Antonio, USA)

    Objective: To examine the use of new Deep Brain Stimulation (DBS) local field potential (LFP) sensing technology for selecting the optimal electrode configuration for stimulation during initial…
  • 2023 International Congress

    Functional circuit abnormalities in Levodopa-induced dyskinesia in Parkinson’s disease: A systematic review

    B. Thomsen, M. Vinding, D. Meder, L. Marner, A. Løkkegaard, H. Siebner (Hvidovre, Denmark)

    Objective: Levodopa-induced dyskinesia (LID) in Parkinson’s disease (PD) are involuntary movements caused by long-term treatment with dopaminergic replacement therapy (levodopa). During the cause of PD,…
  • 2023 International Congress

    Impact of endpoint selection on sample size calculations for disease-modifying clinical trials in Parkinson’s disease patients with GBA1 mutations

    M. Fonseca, G. Castilla-Fernández, J. Liu, J. Holenz, N. Mendonça, D. Simon (Porto, Portugal)

    Objective: To assess clinical trial sample size estimations under variable simulated scenarios for Parkinson’s disease (PD) patients with mutations in the β-glucocerebrosidade gene (GBA1). Background:…
  • 2023 International Congress

    The effect of subthalamic deep brain stimulation on response inhibition and voluntary action control depend on connectivity of the volume of activated tissue with the prefrontal cortex

    J. Waldthaler, A. Sperlich, C. Stüssel, K. Steidel, L. Timmermann, D. Pedrosa (Marburg, Germany)

    Objective: The effect of subthalamic deep brain stimulation on response inhibition and voluntary action control depend on connectivity of the volume of activated tissue with…
  • 2023 International Congress

    No laughing white matter: reduced integrity of the lateral nucleus basalis of Meynert pathway in Parkinson’s disease-related cognitive impairment

    R. Crockett, K. Wilkins, S. Aditham, H. Bronte-Stewart (Stanford, USA)

    Objective: Investigate differences in white matter integrity of the nucleus basalis of Meynert (NBM) tracts in Parkinson’s disease (PD) patients who develop mild cognitive impairment…
  • 2023 International Congress

    What change to expect in duration of benefit per dose when switching from IR CD-LD to IPX203 (ER CD-LD)

    R. Hauser, S. Allard, G. Banisadr, S. Fisher (Tampa, USA)

    Objective: To investigate if duration of benefit (“Good On” time) per dose during immediate-release (IR) carbidopa-levodopa (CD-LD) treatment predicts response to IPX203 conversion. Background: Levodopa’s…
  • 2023 International Congress

    How do recently diagnosed individuals with Parkinson’s self-monitor their Parkinson’s symptoms between consultations?

    J. Domingos, J. Dean, C. Godinho, J. Belo, S. Gow, D. Falconer (Nijmegen, Netherlands)

    Objective: To determine how recently diagnosed people with Parkinson's monitor their Parkinson's symptoms in between medical consultations. Background: Patients monitoring symptoms and reporting them accurately…
  • « Previous Page
  • 1
  • …
  • 138
  • 139
  • 140
  • 141
  • 142
  • …
  • 338
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Welcome to the MDS Abstracts Site
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • An atypical and interesting feature of Parkinson´s disease
  • Patients with Essential Tremor Live Longer than their Relatives
  • Screening and Treatment of Depression in Parkinson’s Disease within Movement Disorders Centers: A Quality Improvement Initiative
    • Help & Support
    • About Us
    • Cookies & Privacy
    • Wiley Job Network
    • Terms & Conditions
    • Advertisers & Agents
    Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
    Wiley